TLDR
- ARK bought 188,665 CoreWeave shares on October 14, worth $14.7 million in the daily trade report.
- CoreWeave stock fell 15.5% and is down 53% over 12 months on debt concerns.
- ARK sold 31,432 Palantir shares after the stock rose more than 60% since early August.
- ARK also sold Personal Genome Diagnostics, 10X Genomics, Toast and Shopify shares.
- Wall Street rates both CoreWeave and Palantir a Moderate Buy.
Cathie Wood’s ARK Invest bought more CoreWeave shares on Wednesday, October 14, 2026. The firm also sold shares of Personal Genome Diagnostics and Palantir Technologies.
CoreWeave, Inc. Class A Common Stock, CRWV
ARK purchased 188,665 CoreWeave shares, valued at $14,680,023 in the daily trade report. Another report put the value at about $12.4 million.
CoreWeave stock fell 15.5% in regular trading on Wednesday. Shares are down 53% over the past 12 months as concerns about the company’s financial obligations weigh on investors.
CoreWeave’s Debt Concerns
The yield on CoreWeave’s $1.25 billion in unsecured bonds due in 2032 recently touched 15%. Venture capitalist Chamath Palihapitiya warned about possible trouble in AI infrastructure financing. Elon Musk replied with one word: “Yikes.”
The Financial Times reported that CoreWeave is exploring financing from life insurance companies. The company hopes to secure investment-grade financing backed by computing infrastructure.
CoreWeave had debt and lease obligations of about $52 billion as of June.
Hotter-than-expected September inflation data also weighed on markets Wednesday. It raised concerns about more Federal Reserve interest rate hikes.
Wall Street rates CoreWeave a Moderate Buy, with 20 Buy ratings, 5 Holds and 2 Sells over the past three months. The average price target of $143.96 is about 119% above Wednesday’s close.
Palantir and Other ARK Trades
ARK sold 31,432 Palantir shares, valued at $6,558,915 in the trade report. Another report put the figure near $6.3 million. Palantir shares fell 3.7% on Wednesday.
The stock has risen more than 60% since early-August earnings. In that report, second-quarter revenue climbed 93% from a year earlier to $1.94 billion.
Barclays recently started coverage of Palantir at Overweight with a $265 price target. Goldman Sachs upgraded the stock to Buy with a $230 target.
Palantir trades at 163.9 times trailing earnings and 85.5 times expected profits. Its average price target of $210.67 points to a 5% gain.
ARK sold 693,049 shares of Personal Genome Diagnostics for $10,984,826. It also sold 113,555 shares of 10X Genomics for $8,152,113.
The firm sold 337,473 shares of Toast for $10,424,540 and 25,605 shares of Shopify for $4,519,794. It bought 9,577 shares of Meta Platforms for $7,302,462.
ARK bought 44,689 shares of Cerebras Systems for $6,662,683 and 110,037 shares of Freenome for $1,390,867. It also added 500,457 shares of Kodiak AI.
ARK bought 459 shares of Scribe Therapeutics for $8,776. CoreWeave shares slipped another 3.5% after hours on Wednesday.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
